p53-Dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with 32P ortho-phosphate in human fibroblasts

Oncogene

Volumn 18, Issue 25, 1999, Pages 3788-3792

  Bond, Jane A ^a   Webley, Katherine ^a   Wyllie, Fiona S ^a   Jones, Christopher J ^a   Craig, Ashley ^b   Hupp, Ted ^b   Wynford Thomas, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cell cycle; DNA damage; Metabolic labelling; p53; Phosphorylation

Indexed keywords

ANTIBODY; DNA; PHOSPHATE; PHOSPHORUS 32; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ARTIFACTS; CELL CYCLE; CELL DIVISION; CELLS, CULTURED; DNA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; FIBROBLASTS; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; ISOTOPE LABELING; PHOSPHATES; PHOSPHORUS RADIOISOTOPES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RESEARCH DESIGN; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033600158     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1202733     Document Type: Article

References (29)

1. Blaydes J and Hupp T. (1998). Oncogene, 17, 1045-1052.
2. Bond JA, Blaydes JP, Rowsow J, Haughton MF, Smith JR, Wynford-Thomas D and Wyllies FS. (1995). Cancer Res., 55, 2404-2409.
3. Bond JA, Haughton M, Blaydes J, Gire V, Wynford-Thomas D and Wyllie F. (1996). Oncogene, 13, 2097-2104.
4. Brady MAW and Finlan MF. (1990). In Situ Hybridization: Principles and Practice, Oxford University Press, UK
5. Cox LS and Lane DP. (1995). Bio. Essays, 17, 501-508.
6. Craig AL and Hupp TR. (1998). 9th p53 Workshop, Crete, p. 102.
7. Dover R, Jayaram Y, Pate K and Chinery R. (1994). J. Cell. Sci., 107, 1181-1184.
8. Gu W and Roeder RG. (1997). Cell. 90, 595-606.
9. Halazonetis T, Waterman M, Chehab N, Caruso L and Stavridi E. (1998). 9th p53 Workshop, Crete, p. 52.
10. Hupp TR and Lane DP. (1994). Cold Spring Harbor Symp. Quant. Biol., 59, 195-206.
11. Hupp TR, Sparks A and Lane DP. (1995). Cell, 83, 237-245.
12. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW. (1991). Cancer Res., 51, 6304-6311.
13. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B. (1992). Science, 256, 827-830.
14. Ko LJ and Prives C. (1996). Genes Dev., 10, 1054-1072.
15. Lu X and Lane DP. (1993). Cell, 75, 765-778.
16. Lutzker SG and Levine AH. (1996). Nature Med., 2, 802-810.
17. Meek D. (1994) Semin. Cancer Biol., 5, 203-210.
18. Milne DM, Campbell LE, Campbell DG and Meek DW. (1995). J. Biol. Chem., 10, 5511-5518.
19. Mundt M, Hupp T, Fritsche M, Merkle C, Hansen S, Lane D and Groner B. (1997). Oncogene, 15, 237-244.
20. Shaw P, Freeman J, Bovey R and Iggo R. (1996). Oncogene, 12, 921-930.
21. Stephen CW, Helminen P and Lane DP. (1995). J. Mol. Biol., 248, 58-78.
22. Vojtesek B, Bartek J, Midgley CA and Lane DP. (1992). J. Immunol. Method, 151, 237-244.
23. Vojtesek B, Dolezalova H, Lauerov L, Svitakova M, Havli P, Kovarik J, Midgley CA and Lane DP. (1995). Oncogene, 10, 389-393.
24. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. (1998). Nature Genet., 19, 175-178.
25. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, and Lee PWK. (1998). Nature, 394, 700-704.
26. Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond J and Wynford-Thomas D. (1993). Mol. Carcinogen., 7, 83-88.
27. Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M and Wynford-Thomas D. (1995). Oncogene, 10, 49-59.
28. Wyllie FS, Haughton MF, Bond JA, Rowson JM, Jones CJ and Wynford-Thomas D. (1996). Oncogene, 12, 1077-1082.
29. Yeargin J and Haas M. (1995). Curr. Biol., 5, 423-431